Switch from Enfuvirtide to Raltegravir
CHEER Trial
## Study Design: CHEER

### Background
Prospective, nonrandomized, open-label, historical control study evaluating switch from enfuvirtide to raltegravir in virologically suppressed HIV-infected patients.

### Inclusion Criteria (n = 52)
- Age ≥ 18
- HIV RNA < 50 copies/mL (by PCR) or < 75 copies/mL (by bDNA) for ≥ 6 months
- No prior treatment with integrase inhibitors

### Treatment Arm
- Raltegravir + background antiretroviral regimen (patients served as own controls)

---

Switch from Enfuvirtide to Raltegravir
CHEER: Results

Week 24: Virologic Response (Non-completer=Failure, ITT Analysis)

**Conclusions**: “In treatment-experienced patients on a stable virologically suppressive enfuvirtide-containing regimen, raltegravir can safely be substituted for enfuvirtide.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*